The DOI matches its Crossref record.
Survival of Patients with Non-Small-Cell Lung Cancer after a Diagnosis of Brain Metastases
Open accessAbstract
Background: The prognosis of patients with brain metastases from non-small-cell lung cancer (NSCLC) is poor. However, some reports suggest that patients with brain metastases at the time of initial diagnosis have a more favourable survival than do patients with advanced NSCLC without brain metastases. Methods: In a retrospective cohort of all new lung cancer patients seen at a Canadian tertiary centre between July 2005 and June 2007, we examined survival after a diagnosis of brain metastases for patients with brain metastases at initial diagnosis and patients who developed brain metastases later in their illness. Results: During the 2-year period, 91 of 878 patients (10.4%) developed brain metastases. Median age in this cohort was 64 years. In 45, brain metastases were present at initial diagnosis, and in 46, brain metastases developed later in the course of the illness. Median survival in the entire cohort was 7.8 months. Survival after the diagnosis of brain metastases was similar for patients with brain metastases at diagnosis and later in the illness (4.8 months vs. 3.7 months, p = 0.53). As a result, patients who developed brain metastases later in their illness had a longer overall survival than did patients with brain metastases at diagnosis (9.8 months vs. 4.8 months). Among patients who received chemotherapy, the survival of patients with brain metastases at diagnosis was still poor (6.2 months). Conclusions: Our data show limited survival in patients with brain metastases from NSCLC. Careful patient selection for more aggressive treatment approaches is necessary.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The lung microenvironment: an important regulator of tumour growth and metastasis
Altorki, N. K., Markowitz, G. J., Gao, D., Port, J. L., Saxena, A., Stiles, B., McGraw, T., & Mittal, V. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-018-0081-9 · Cited by 1,150
First-Line Lorlatinib or Crizotinib in Advanced ALK -Positive Lung Cancer
Shaw, A. T., Bauer, T. M., de Marinis, F., Felip, E., Goto, Y., Liu, G., Mazieres, J., Kim, D.-W., Mok, T., Polli, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2027187 · Cited by 1,099
Capmatinib in MET Exon 14–Mutated or MET -Amplified Non–Small-Cell Lung Cancer
Wolf, J., Seto, T., Han, J.-Y., Reguart, N., Garon, E. B., Groen, H. J. M., Tan, D. S. W., Hida, T., de Jonge, M., Orlov, S. V., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002787 · Cited by 1,000
Schuler, M., Wu, Y.-L., Hirsh, V., O’Byrne, K., Yamamoto, N., Mok, T., Popat, S., Sequist, L. V., Massey, D., Zazulina, V., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2015.11.014 · Cited by 361
Metadata
- Authors
- Ali, A., Goffin, J. R., Arnold, A., & Ellis, P. M.
- Venue
- Current Oncology
- Publisher
- MDPI AG
- Published
- 2013-08-01
- Volume
- 20
- Issue
- 4
- Pages
- 300-306
- ISSN
- 1198-0052 (ISSN-L)
- 1718-7729
- OpenAlex
- W1964127544
- Cited by
- 235
- References
- 0
- FWCI
- 5.12
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Survival of Patients with Non-Small-Cell Lung Cancer after a Diagnosis of Brain Metastases. https://app.cochat.ai/papers/10.3747/co.20.1481
- The paper
- Ali, A., Goffin, J. R., Arnold, A., & Ellis, P. M. (2013). Survival of Patients with Non-Small-Cell Lung Cancer after a Diagnosis of Brain Metastases. Current Oncology. https://doi.org/10.3747/co.20.1481
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.